(366) Effect of Pegylayion on liposomal adhesion on breast cancer tumor

In 2022, breast cancer affected 2.29 million women causing 700,000 deaths globally, with incidence rising. Its heterogeneity and variability complicate targeted therapy development, with 90% of new drugs failing clinical trials. The tumor extracellular matrix (ECM) is central in tumor progression, modulating the microenvironment while providing structural support. Variations in the ECM may affect drug uptake, reducing efficacy. Here we developed a method to characterize and quantify the physicochemical properties of breast cancer ECM and its interactions with nanosized drug delivery vehicles.